CEBPA and acute myeloid leukemia: Firstly, we only examine genes of FLT3-ITD, NPM1, CEBPA and DNMT3A mutations, thus we could not exclude other genes like IDH1/2, TET2, ASXL1 mutations those will confound the prognostic value of HIP1 expression in AML patients.